Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies

Over the past few decades, immunotherapy has revolutionized the modern medical oncology field. Chimeric antigen receptor (CAR)-T cell therapy has a promising curative effect in the treatment of hematological malignancies. Anti-CD19 CAR-T cells are the most mature CAR-T cells recently studied and in...

Full description

Bibliographic Details
Main Authors:	Danni Xie BD, Xin Jin PhD, Rui Sun MM, Meng Zhang MM, Jiaxi Wang BD, Xia Xiong MM, Xiaomei Zhang MM, Mingfeng Zhao PhD, MD
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-08-01
Series:	Technology in Cancer Research & Treatment
Online Access:	https://doi.org/10.1177/15330338221118413

Similar Items

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies
by: Haiqiong Zheng, et al.
Published: (2024-11-01)

The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis
by: Jile Liu, et al.
Published: (2025-01-01)

Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy
by: Linghui Zhou, et al.
Published: (2022-06-01)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
by: Samane Abbasi, et al.
Published: (2023-04-01)

Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
by: Zhihuan Yang, et al.
Published: (2023-10-01)

Solitary Metastatic Carcinoma of Colon from Renal Cell Carcinoma Misdiagnosed as Primary Colon Carcinoma
by: Yemei He, MM, Danni He, MM, Xuankun Liang, MM, Zuofeng Xu, MD, PhD
Published: (2023-09-01)

Chimeric Antigen Receptor T Cell Therapy in Hematology
by: Pınar Ataca, et al.
Published: (2015-11-01)

Bone marrow transplantation versus chimeric antigen receptor T cells (CAR-T) therapy for hematological malignancies
by: Arnon Nagler, M.D., M.SC, et al.
Published: (2023-10-01)

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience
by: Wei Sun, et al.
Published: (2023-02-01)

The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
by: Elaine Tan Su Yin, et al.
Published: (2022-06-01)

Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy
by: Lei Xue, et al.
Published: (2021-09-01)

Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy
by: Luzhen Li, MM, et al.
Published: (2022-06-01)

P1466: CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED T CELL MALIGNANCIES
by: Y. Zhang, et al.
Published: (2022-06-01)

Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
by: Feng Zhu, et al.
Published: (2020-04-01)

Lifestyle and ADL Are Prioritized Factors Influencing All-Cause Mortality Risk Among Oldest Old: A Population-Based Cohort Study
by: Zhiwen Ge MM, et al.
Published: (2024-02-01)

Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current progress
by: Emmanuelle Tchernonog, et al.
Published: (2024-03-01)

Plasma CircCYP24A1 as a Novel Biomarker of Esophageal Squamous Cell Carcinoma
by: Ruolan Zhang M.M., et al.
Published: (2024-12-01)

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
by: Gils Roex, et al.
Published: (2020-02-01)

Association of ERCC5 Genetic Polymorphisms With Cirrhosis and Liver Cancer
by: Gang Yang MM, et al.
Published: (2020-08-01)

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies
by: Dong Zhao PhD, et al.
Published: (2023-12-01)

Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review
by: Fabio Efficace, et al.
Published: (2022-12-01)

Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies
by: Ettore Biagi, et al.
Published: (2007-03-01)

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
by: Diwei Zheng, et al.
Published: (2022-05-01)

Role of Radiation in Combination With CD30-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma
by: Colton Ladbury, MD, et al.
Published: (2024-04-01)

Risk Factors and Predictive Model for Disseminated Intravascular Coagulation in Patients with Multiple Myeloma
by: Rong Bao MM, et al.
Published: (2025-02-01)

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
by: Ali Keshavarz, et al.
Published: (2022-09-01)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
by: David L Porter, Michael Kalos, Zhaohui Zheng, Bruce Levine, Carl June
Published: (2011-01-01)

A Potential Tumor Suppressor Gene Named miR-508-5p Inhibited the Proliferation and Invasion of Human Melanoma Cells by Targeting KIT
by: Lin Dang PhD, et al.
Published: (2020-09-01)

Low Tumor Infiltrating Mast Cell Density Reveals Prognostic Benefit in Cervical Carcinoma
by: Fan Guo PhD, et al.
Published: (2022-06-01)

The Value of Dual-Energy Computed Tomography-Based Radiomics in the Evaluation of Interstitial Fibers of Clear Cell Renal Carcinoma
by: Xue Bing MM, et al.
Published: (2024-02-01)

Risk Prediction Models for Preoperative Deep Vein Thrombosis in Older Patients with Hip Fracture: A Systematic Review and Meta-Analysis
by: Huali Guo MM, et al.
Published: (2024-09-01)

MiR-331-3p Links to Drug Resistance of Pancreatic Cancer Cells by Activating WNT/β-Catenin Signal via ST7L
by: Ting Zhan MM, et al.
Published: (2020-09-01)

Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
by: Jing Ding, et al.
Published: (2022-09-01)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
by: Jin Zhou, et al.
Published: (2022-09-01)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
by: Elad Jacoby
Published: (2019-06-01)

The Role of Myeloid-Derived Suppressor Cells in the Treatment of Pancreatic Cancer
by: Peng Dong MM, et al.
Published: (2022-12-01)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
by: Michael M. Boyiadzis, et al.
Published: (2018-12-01)

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer
by: Limeng Yu MM, et al.
Published: (2023-04-01)

LC3B in Malignant Cells Correlates With Immune Infiltrate in Hypopharyngeal Squamous Cell Carcinoma
by: Sifan Gao MM, et al.
Published: (2020-11-01)

Patient-reported outcomes of chimeric antigen receptor T-cell therapy in hematologic malignancies: a systematic review and meta-analysis
by: Hyo Jung Park, et al.
Published: (2024-10-01)